monday.com Ltd., together with its subsidiaries, develops software applications in the United States, Europe, the Middle East, Africa, the United Kingdom, and internationally.
FAIL · Does not pass the screen
96.80 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · 5 Nov · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price96.80 USD at the 4 Nov 2026 close
Our value readUndervalued vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.51, read 2026-11-02
Ethical does not pass the values gate
Price96.80 USD
Fair value131.25
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-25Read Markup100.86-4.0% to today Accumulation gives way to Markup after a 19% rise in 7 days
2026-10-18Read Accumulation84.69+14.3% to today ✓Markup gives way to Accumulation after a 7% rise in 7 days
2026-10-11Read Markup78.80+22.8% to today ✓Distribution gives way to Markup after a 10% slide in 9 days
2026-10-02Read Distribution87.96+10.1% to today Markup gives way to Distribution after a 13% rise in 13 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
monday.com Ltd. holds its Markup at $96.80. Consolidating, no directional conviction, held for 138 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 138 days
Price at the screen
$96.80
Valuation
40.84 trailing · 14.45 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.06
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.01%
Below 33%
Interest-bearing debt is just 8.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
7.70%
Below 33%
Cash held in interest-bearing accounts and securities is 7.7% of assets, under the one-third limit.
Pass
Receivables
72.80%
Below 49%
Money owed to the company is 72.8% of assets, above the 49% limit.
Fail
Revenue purity
5.28%
Below 5%
5.3% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
monday.com's business is fine, but its receivables are about 73% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MNDY's ethical verdict changes
Today MNDY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement as an Israeli-headquartered technology company. Founded in Tel Aviv with significant Israeli operations. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 26% discount to our $131.25 fair value, 21.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 26.2% discount to the base estimate.
Where our models see it going: fair-value estimate $131.25, with a range of $130.62 to $193.60, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Work Software Platform Looks Cheap But We Pass
Teams juggling tasks across continents still rely on clunky spreadsheets and scattered apps to stay aligned. monday.com offers a cloud based work operating system that tries to pull everything into one visual space. Yet the opportunity rating sits at none, so we pass despite the numbers.
Revenue grows at 24 percent with a forward multiple of just 14.6 times and a 9 percent profit margin. Return on equity reaches 13 percent while the ethical screen clears cleanly. Analysts lean buy with a 102 dollar median target against our 121 dollar fair value, but the unknown moat leaves too much uncertainty for any real conviction.
Currency swings from its Israeli base and competition from bigger platforms add real downside. Low margins also leave little room if growth slows. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Israel and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MNDY trades on Nasdaq (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$95.60-5.2%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114. Insiders have been net sellers over the past quarter.
2026-10-25Markup · changed$100.86+19.1%Entry 9
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114.
2026-10-11Markup · changed$78.80-10.4%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114.
2026-09-05Markup$92.55+17.6%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114.
2026-08-05Markup$78.69+1.4%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114.
2026-07-18Markup$77.57+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (25 analysts) rates it buy, with a mean price target of $114.
2026-07-03Markup$77.57+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$77.57Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
